Expert panelists consider how to define response to disease-modifying therapies and discuss the threshold for treatment ineligibility due to lack of response. Neil Minkoff, MD: At some point, we are ...

Oncologists use measurement of response as an indicator that the therapy they are administering is effective. This information can then be used to decide whether to continue, change, or stop therapy ...

To determine the average time-point at which it is best to define ‘sub-optimal response’ after ranibizumab treatment for diabetic macular edema (DME) based on the data obtained from real-life clinical ...